Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil in Duchenne Muscular Dystrophy – CORRECTION
April 10, 2026 16:09 ET | Source: Mesoblast Limited Working with Parent…
Real-World Commercial Experience with Ryoncil Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
January 26, 2026 18:45 ET | Source: Mesoblast Limited NEW YORK, Jan.…
